Cargando…

DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy

BACKGROUND: The most common form of facioscapulohumeral muscular dystrophy (FSHD) is caused by a genetic contraction of the polymorphic D4Z4 macrosatellite repeat array in the subtelomeric region of chromosome 4q. In some studies, genes centromeric to the D4Z4 repeat array have been reported to be o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thijssen, Peter E, Balog, Judit, Yao, Zizhen, Pham, Tan Phát, Tawil, Rabi, Tapscott, Stephen J, Van der Maarel, Silvère M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364343/ https://www.ncbi.nlm.nih.gov/pubmed/25789155 http://dx.doi.org/10.1186/2044-5040-4-19

Ejemplares similares

A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
por: Feng, Qing, et al.
Publicado: (2015)

Facioscapulohumeral dystrophy: the path to consensus on pathophysiology
por: Tawil, Rabi, et al.
Publicado: (2014)

Adenine base editing of the DUX4 polyadenylation signal for targeted genetic therapy in facioscapulohumeral muscular dystrophy
por: Šikrová, Darina, et al.
Publicado: (2021)

Immunohistochemical Characterization of FacioscapulohumeralMuscular Dystrophy Muscle Biopsies
por: Statland, Jeffrey M., et al.
Publicado: (2015)

DUX4 Binding to Retroelements Creates Promoters That Are Active in FSHD Muscle and Testis
por: Young, Janet M., et al.
Publicado: (2013)

Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Jones, Takako I., et al.
Publicado: (2016)

Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy
por: Bouwman, Linde F., et al.
Publicado: (2021)

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
por: Greco, Anna, et al.
Publicado: (2020)

A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics
por: Campbell, Amy E., et al.
Publicado: (2023)

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments
por: Duranti, Elisa, et al.
Publicado: (2023)

Facioscapulohumeral Dystrophy: Incomplete Suppression of a Retrotransposed Gene
por: Snider, Lauren, et al.
Publicado: (2010)

DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy
por: Shadle, Sean C., et al.
Publicado: (2017)

Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
por: Chen, Jennifer CJ, et al.
Publicado: (2016)

Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
por: Banerji, Christopher R S, et al.
Publicado: (2021)

Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy
por: Wang, Leo H., et al.
Publicado: (2021)

Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy
por: Himeda, Charis L., et al.
Publicado: (2018)

A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020)

Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity
por: Banerji, Christopher R S, et al.
Publicado: (2020)

Telomere Position Effect (TPE) Regulates DUX4 in Human Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Stadler, Guido, et al.
Publicado: (2013)

p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy
por: Bosnakovski, Darko, et al.
Publicado: (2017)

A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy
por: Jones, Takako, et al.
Publicado: (2018)

Rbfox1 Downregulation and Altered Calpain 3 Splicing by FRG1 in a Mouse Model of Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Pistoni, Mariaelena, et al.
Publicado: (2013)

CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy
por: Das, Sunny, et al.
Publicado: (2021)

Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
por: Ganassi, Massimo, et al.
Publicado: (2022)

Increased DUX4 expression during muscle differentiation correlates with decreased SMCHD1 protein levels at D4Z4
por: Balog, Judit, et al.
Publicado: (2015)

Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients
por: Signorelli, M., et al.
Publicado: (2020)

Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models
por: Nunes, Andreia M., et al.
Publicado: (2021)

Determining the role of sarcomeric proteins in facioscapulohumeral muscular dystrophy: a study protocol
por: Lassche, Saskia, et al.
Publicado: (2013)

Ophthalmological findings in facioscapulohumeral dystrophy
por: Goselink, Rianne J M, et al.
Publicado: (2019)

NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins
por: Campbell, Amy E, et al.
Publicado: (2018)

The facioscapulohumeral muscular dystrophy Rasch‐built overall disability scale (FSHD‐RODS)
por: Mul, Karlien, et al.
Publicado: (2021)

Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2
por: Lemmers, Richard J.L.F., et al.
Publicado: (2012)

Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation
por: Bodega, Beatrice, et al.
Publicado: (2009)

Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy
por: Jagannathan, Sujatha, et al.
Publicado: (2019)

A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4
por: Sasaki-Honda, Mitsuru, et al.
Publicado: (2018)

Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity
por: Jones, Takako I., et al.
Publicado: (2020)

Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy
por: Statland, Jeffrey M., et al.
Publicado: (2022)

Treatment of facioscapulohumeral muscular dystrophy with Denosumab
por: Lefkowitz, Stanley S., et al.
Publicado: (2012)

Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy
por: Vera, Kathryn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mn6s49aad7f1a8j7bl4ebmhuvq